Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-04
2005-01-04
Pryor, Alton N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
06838434
ABSTRACT:
A sinus headache can be treated by administration of abotulinumtoxin to a patient. Thebotulinumtoxin can bebotulinumtoxin type A and thebotulinumtoxin can be administered to or to the vicinity of a sinus membrane of a patient with a sinus headache.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 20020036943 (2002-03-01), Fujimoto
patent: 20020187164 (2002-12-01), Borodic
patent: 20020192239 (2002-12-01), Borodic et al.
patent: 20020197278 (2002-12-01), Allison
patent: 20020197279 (2002-12-01), Aoki et al.
patent: 20030143249 (2003-07-01), Lamb
Anderson, T. et al., Surgical Intervention for Sinusitis in Adults;Current Allergy and Asthma Reports;2001, 1:282-288.
Aoki, K.R. et al., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions;European Journal Neurology;2001; 8 (Suppl 5):pp 21-29.
Aoki, K.R.; Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins; In: Kreyden OP, ed.Hyperhidrosis and Botulinum Toxin in Dermatology;Current Problems in Dermatology; Basel, Karger; 2002; 30: pp. 107-116.
Bigalke, Hans et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Res;1985; 360: pp 381-24.
Bigalke, H. et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn Schmiedebergs Arch Pharmacol;1981; 316; pp 244-51.
Binz, Thomas et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins;J Biochem;(Tokyo) Jun. 5, 1990; 265(16); pp 9153-8.
Borodic, et al., Management of facial pain with botulinum toxin in a tertiary pain clinic,Naunyn Schmiedebergs Arch Pharmacol,2002;365(Suppl 2):R14.
Brem, Henry et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas;The Lancet;vol. 345; Apr. 22, 1995; pp 1008-1012.
Brin, Mitchell F. et al., Botulinum Toxin Type A: Pharmacology; In: Mayer Nathaniel H, ed.Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin;2002; pp 110-124.
Bushara, K.O., Botulinum Toxin and Rhinorrhea;Otolaryngol Head Neck Surg;1996; 114(3): 507.
Cui, M. et al., Mechanisms of the Antinociceptive Effect of Subcutanous Botox®: Inhibition of Peripheral and Central Nociceptive Processing;Naunyn Schmiedebergs Arch Pharmacol;2002; 365 (Suppl 2) R17; Abstract.
Moyer, Elizabeth et al., Botulinum Toxin Type B: Experimental and Clinical Experience; In: Jankovic J, ed.Neurological Disease and Therapy. Therapy with botulinum toxin;1994; 25; pp 71-85.
Naumann, Markus et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions;European Journal of Neurology;1999, vol. 6 (suppl 4) pp S111-5.
Pearce, Bruce et al., Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine;Toxicon;1997; 35(9); pp 1373-412.
Ragona, Rosario M. et al., Management of Parotid Sialocele With Boutulinum Toxin;Laryngoscope;109; Aug. 1999 (8); pp 1344-1346.
Rollnik, J.D., et al., Botulinum Toxin (DYSPORT) in Tension-type headaches,Acta Neurochir,2002;79(Suppl):123-126.
Rohrbach, S., et al., Minimally invasive application of botulinum toxin type A in nasal hypersecretion,J Oto-Rhino-Laryngol2001, Nov.-Dec.;63(6):382-4.
Sanchez-Prieto, Jose et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes;Eur J Biochem;Jun. 1987; 165 (3); pp 675-81.
Schantz, Edward J. et al., Properties and Use of Boulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiol Review;Mar. 1992; 56 (1); pp 80-99.
Singh, Bal Ram; Critical Aspects of Bacterial Protein Toxins;Natural Toxins II;Edited by B. R. Singh et al., Plenum Press, New Yrok, 1996; Chapter 4, pp 63-84.
Sloop, R. et al., Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use;Neurology;Jan. 1997; 48(1): 249-53.
Thant, Z-S., et al., Emerging therapeutic applications of botulinum toxin,Med Sci Monit 2003,Janj;9(2):RA40-RA48.
Wiegand, H. et al., I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after intramuscular Injection;Naunyn Schmiedebergs Arch Pharmacol;1976; 292; pp 161-5.
PDF file from website www.imigaine.net/patient/guide.pdf on Mar. 13, 2003,Wake Forest University Baptist Med Center, Dept. of Neurology;Headache: A Patient's Guide, 15 pgs.
Duggan, Michael J. et al., A survey of botulinum neurotoxin substrate expression in cells;Mov Disord;May 1995; 10(3) p. 376.
Evers, S., et al., Treatment of headache with botulinum toxin A—a review according to evidence-based medicine criteria,Cephalalgia 2002,Nov.;22(9): 699-710.
Fauci et al.,Harrison's Principles of Internal Medicine; 14thed.
Ferrari, David M. et al., The protein disulphide-isomerase family: unravelling a string of folds;Biochem J;1999 (339) pp 1-10.
Freund, B.J., et al. The use of botulinum toxin-A in the treatment of refractory cluster headache: case reports,Cephalagia 2000;20(4):329-330, p. 159.
Freund, B.J., et al., Relief of tension-type headache symptoms in subjects with tempooromandibular disorders treated with botulinum toxin-A,Headache 2002Nov.-Dec.; 42(10):1033-1037.
Freund, B.J., Treatment of Chronic Cervical—Associated headache with botulinum toxin A: a pilot study,Headache 2000,Mar.; 40(3):231-236.
Fung, Lawrence K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer implant in the Monkey Brain;Cancer Research;58, Feb. 15, 1998; pp 672-684.
Guyton, Arthur C. et al.,Textbook of Medical Physiology 9th ed;W.B. Saunders Company; pp 686-688.
Habermann, E., I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn Schmiedeberg's Arch. Pharmacol;1974; (281); pp 47-56.
Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H} GABA from rat brain homogenate;Experientia;Mar. 15, 1988; 44(3) pp 224-6.
Habermann, E. et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain;J Neurochem;vol. 51 No. 2 1988; pp 522-7.
Loder, E., et al., Use of botulinum toxins for chronic headaches: a focused review,Clin J Pain 2002; 18(6 Suppl): S169-S176.
Jankovic, Joseph et al.,Therapy with Botulinum Toxin;Marcel Dekker, Inc.; pp 5 and 150.
Marjama-Lyons, J. et al., Tremor-Predominant parkinson's Disease;Drugs&Aging;Apr. 16, 2000; (4); 273-278.
Mathew, N.T., et al., The use of botulinum toxin type A in headache treatment,Curr Treat Options Neurol 2002Sep.;4(5):365-373.
Allergan Inc.
Donovan Stephen
Pryor Alton N.
LandOfFree
Methods for treating sinus headache does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating sinus headache, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating sinus headache will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3414120